Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.

CONCLUSION: This study showed improved survival outcomes compared to our previous study (37.7 vs. 12 months), suggesting that the use of a novel agent as induction and maintenance therapy may be beneficial in patients with IgD MM who undergo ASCT. PMID: 29635247 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29635247?dopt=Abstract

Source: Acta Haematologica - April 10, 2018 Category: Hematology Authors: Kang J, Hong JY, Yoon DH, Kim S, Lee KM, Park JS, Park CJ, Min WK, Seo EJ, Jang S, Suh C Tags: Acta Haematol Source Type: research